We are pleased to announce the recent appointments of Maria V. Cincotta as our VP of Clinical Operations & Program Management and Tu-Anh T. Bui as our VP of CMC & Technical Operations.

Ms. Cincotta brings over 25 years of experience in directing international clinical trials and program oversight in the biotech and pharma settings. Before joining Tagworks Pharmaceuticals, she was VP Global Clinical Science and Operations at ADC Therapeutics where she was closely involved in the successful approval of Zynlonta® within 6 years of initiating first-in-human clinical trials. Ms. Cincotta held various positions within oncology clinical development during her tenure at Wyeth, and has provided clinical operations consulting services for oncology focused companies in the Boston area where she is based.   
https://www.tagworkspharma.com/team/maria-cincotta

Ms. Bui has more than 15 years of experience in biopharmaceutical CMC leadership roles, shaping technical CMC for a diverse portfolio of products including vaccines, antibodies and ADCs. Her tenure includes Synthon (aka Byondis), Merck & Co and Chinook Therapeutics (acquired by Novartis), where she had the position of Sr. Director CMC & Technical Operations and led the advancement of an antibody product from early to late-stage clinical development. She has successfully navigated projects from target identification to commercial launch.
https://www.tagworkspharma.com/team/tu-anh-bui

The expertise of Ms. Cincotta and Ms. Bui support the ambition of Tagworks Pharmaceuticals to change the standard of care for patients suffering from severe diseases including cancer by building a pipeline of first-in-class Click-to-Release therapeutics.

We feel privileged to welcome Maria and Tu-Anh to our company!